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POPULAR SCIENCE SUMMARY OF THE THESIS 
Virus outbreaks have always been a threat to mankind. The Spanish flu at the beginning of the 
20th century, the Zika virus outbreak in the Americas in 2015, or the Ebola virus outbreak in 
2016 in West Africa are only a few examples. Likewise, the ongoing COVID-19 pandemic has 
brought unprecedented social and economic disruptions to countries all over the globe and has 
brought to public attention that we are not well prepared for new virus outbreaks. In particular 
medicines are missing to treat infected people, as well as easily adaptable diagnostic tests, to 
enable fast set up of large-scale testing. Fast diagnosis is not only important to diagnose a virus 
disease in a patient, but also to assess the spread in the population and steer the response to a 
pandemic.  
A big obstacle to the development of medication and diagnostic tests for viruses is the lack of 
good models to study viruses. In biology models are substitute organisms that are studied 
extensively to understand biological phenomena, human disease or in the case of pathogens, 
understand the behavior and effects of pathogens in humans. Models are widely used in 
research, because it can be unethical or unfeasible to do certain experiments in humans. The 
underlying assumption is that the findings from models are transferable to human disease. 
However, what complicates matters for virus research is that viruses can be very selective about 
the species they infect, and the disease viruses cause is not the same in all species. The work 
from this thesis highlights how different models can be used to speed up the development of 
new medication and diagnostic tools for viruses.  
When viruses infect cells, they create certain observable traits, also called phenotypes. For 
example, the virus can be detected inside cells using fluorescent antibodies, and thus infected 
and uninfected cells can be distinguished and counted when images of the cells are taken. This 
principle was used in the first paper included in the thesis. A total of 425 compounds were 
tested for their antiviral properties by checking if they reduce signal from fluorescent antibodies 
against virus inside infected cells. This way, we found two substances with an antiviral effect. 
Subsequently, using the same method but different viruses, we confirmed that the two 
substances identified do not only work against a single virus. We discovered that the substances 
have activity against several viruses including Ebola and SARS-CoV-2 virus, the virus which 
is causing the COVID-19 pandemic.  
The second paper focused on the action of the newly discovered antivirals against Zika virus. 
First, we confirmed that these substances were active against Zika virus. Zika virus can cause 
a small brain in children by infecting their brain cells, also called neurons, if their mother is 
infected with Zika virus during pregnancy. To mimic this, we used cells derived from human 
brain tumors to study the antiviral substances and confirmed that they have an antiviral effect 
against Zika virus.  
However, the brain is the body’s most complex organ. This complexity makes it very difficult 
to find a suitable model for the human brain. The brain tumor cells we used previously are very 
homogenous and one-dimensional, while the brain is a three-dimensional organ with many 
different types of cells which communicate with each other. While this is difficult to model in 
traditional cell culture, in the past decade three-dimensional organoids have become available. 
It has been shown previously that brain organoids are a great model for Zika virus: just as in 
the fetal brain, Zika virus is able to infect neurons in the organoids and reduce their viability. 
We were able to show that our compounds not only reduce the amount of Zika virus in the 
organoids but also restore organoid viability.  
The third study from this doctoral thesis focused on the development of a new diagnostic tool 
to detect Zika virus by multiplying parts of its genome. In the development of the diagnostic 
tool, both cell lines and blood cells from healthy donors were infected artificially in the lab to 
generate samples to test the new approach for sensitivity. Infecting blood cells from healthy 
donors with virus mimics the real infection in the patients, and the Zika virus levels found in 
the artificially infected samples resemble the ones found in patients. This approach helps 
research groups to develop diagnostic tools even without access to patient samples, which are 
not easy to acquire, especially for infections from remote regions or low-income countries.  
Altogether, the first two studies highlight the use of different cell and organoid models to 
advance antiviral drug development. The third study focuses on developing new diagnostics 
for Zika virus using cells and human blood as a model. These approaches contribute to 






The ongoing global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) is only the latest reminder of the urgent need for new antiviral strategies and diagnostic 
tools to improve preparedness for emergence of new pathogenic RNA-viruses. A key obstacle 
for the development of antivirals and diagnostic tools has been the lack of good models to study 
RNA viruses. This thesis focused on cellular and organoid models for virus infection to 
facilitate the development of host-targeting antivirals and new diagnostic tools against 
emerging viruses. 
In Paper I, two close analogues from an in-house library of 425 host-targeting compounds 
were found to have antiviral activity against apathogenic RNA virus Hazara virus (HAZV). 
These two hit compounds were discovered using a cell- and image-based phenotypic antiviral 
screening assay. Subsequently, the two compounds were confirmed to have a broad-spectrum 
antiviral activity against several pathogenic RNA viruses including SARS-CoV-2, Ebola and 
Crimean-Congo hemorrhagic fever virus. After showing the independence of the compound’s 
antiviral effect of their originally designed target, human 8-oxoguanine glycosylase 1, thermal 
protein profiling was used to study the compound target. Applying this technique, the 
compound was revealed to disturb proteostasis pathways and interactions between cellular heat 
shock protein 70 complex and viral proteins.  
In Paper II, a second antiviral screening of in-house compounds was performed using the 
previously established image-based phenotypic antiviral screening assay with Zika virus 
(ZIKV) infected cells. The broad-spectrum activity of the compounds was confirmed by 
revealing the same compounds to be active against both HAZV and ZIKV. Next, the 
therapeutic window and antiviral activity of the top-hit compounds was demonstrated in several 
cellular models of ZIKV infection. Additionally, the novel antiviral compounds showed an 
antiviral effect and reversed ZIKV induced neurotoxicity in iPS cell derived human brain 
organoids. Furthermore, mechanism-of-action studies revealed the compound to impair the 
formation of new virus particles in the late lifecycle steps. 
In Paper III, the development of a new diagnostic tool for ZIKV is described using in vitro 
infected U87 cells and PBMCs. In the method presented, ZIKV cDNA was hybridized using 
padlock probes and amplified by two rounds of Circle-to-Circle Amplification. Detection was 
performed using a microfluidic affinity chromatography enrichment platform. Benchmarking 
of the newly developed method against RT-qPCR, the gold standard diagnostic method for 
ZIKV detection, confirmed a good correlation between both methods.  
Altogether, this thesis demonstrates how cell culture tools with varying complexity, unique 
advantages and challenges can be used to augment the development of novel antiviral drugs 
and diagnostic methods.  
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1.1 GENERAL INTRODUCTION TO EMERGING VIRUSES 
The currently ongoing global pandemic of Coronavirus diseases 2019 (COVID-19) caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is only the latest example of 
the significant public health threat posed by emerging pathogens. In the last decade, we have 
seen outbreaks of several pathogenic RNA viruses like SARS causing pneumonia, Ebola virus 
(EBOV) causing lethal hemorrhagic fever and Zika virus (ZIKV) causing congenital Zika 
syndrome (CZS), to name just a few prominent examples. Viral emergence is driven by 
increasing urbanization, rapid population growth, increased travelling activities, as well as 
climate change and global warming. All of these man-made problems entail a spread of vectors 
to previously unaffected areas.  
Common denominators of emerging RNA viruses are the lack of vaccines, available therapies 
and in-depth knowledge about the pathogenesis, host reactions and underlying molecular 
events. New insights and approaches are needed to develop therapeutic strategies towards these 
inevitable global threats.  
1.2 ZIKA VIRUS  
1.2.1 Epidemiology & outbreaks 
ZIKV was first isolated in 1947 in Uganda (1). It is an arbovirus and belongs to Flaviviridae 
family (2). Mosquito species Aedes aegypti and Aedes albopictus are natural vectors of ZIKV 
infection, therefore ZIKV spread is closely linked to the spread of these vectors in the tropical 
regions of the world, between 23.5°S and 23.5°N latitude (3). However, several other 
transmission modes have also been reported for ZIKV, including blood transfusions (4), sexual 
intercourse (5) and maternal-fetal transmission (6). 
For decades after it was first isolated, ZIKV was associated with few cases of very mild human 
disease, until it caused outbreaks in Yap state, Micronesia in 2007 (7) and subsequently a much 
bigger outbreak in French Polynesia in 2013, with more than 30,000 people infected (8,9). 
During this outbreak ZIKV was linked to serious neurological complications for the first time    
(10,11). From French Polynesia, the virus was brought to Brazil by travel, most likely in the 
end of 2014. The combination of a previously unexposed and thus unprotected population and 
other factors like the low activity in vector control measures led to an exploding epidemic with 
ca. 1.5 million people infected (12,13). 
Given its described evolution, ZIKV is a particularly interesting and serious example of viral 
emergence, and the transition of a “harmless” and presumably unimportant pathogen to a public 
health threat on a global scale.  
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1.2.2 Clinical implications of ZIKV infection 
For the majority of patients, ZIKV infection remains harmless: most cases are believed to be 
asymptomatic or cause a self-limiting, very mild disease (14). In these patients the most 
common symptoms include fever, conjunctivitis, headache, pruriginous maculo-papular rash, 
arthralgia and myalgia (2,15,16). 
Nevertheless, even asymptomatic and self-limiting diseases can be detrimental for women who 
are pregnant at the time of ZIKV infection, because of the dramatic effect for the fetus (17). 
ZIKV has been shown to be teratogenic, lead to miscarriages (18) and cause a disease complex 
named Congenital Zika Syndrome (CZS) (15). CZS collectively describes various neurological 
complications in newborns following ZIKV infection of the mother during pregnancy (19). 
These pathologies are the result of neuronal cell death in fetuses following ZIKV infection. 
The hallmark of CZS is microcephaly (20,21), a reduction in brain volume and subsequently 
also the cranial structures (22). CZS also features structural eye anomalies and posterior ocular 
lesions like chorioretinal and optic nerve atrophy (23,24), as well as congenital contractures 
(25).  
However, studies have demonstrated that only 2.5-5% of babies born to mothers with ZIKV 
infection during their pregnancy develop birth defects (26,27). In the rest of the cases, the 
babies do not suffer from CZS, despite a maternal ZIKV infection during pregnancy. It is 
unclear if the maternal immune system is able to clear the infection prior to a transplacental 
infection of the fetus, or if despite the infection the fetuses do not develop disease. One 
contributing factor seems to be the stage of pregnancy at the time of infection. While up to 15% 
of babies of mothers infected during the first trimester develop neurological defects, the 
percentage declines in later pregnancy stages. Moreover, not all neuronal damage presents as 
CZS. Large long-term studies will be needed to assess if children with no clear CZS symptoms 
at birth might still suffer from more subtle signs of fetal neuronal damage like learning 
difficulties, mental health problems or social problems.  
In adults, ZIKV infection has been linked to a serious neurological complication, named 
Guillain-Barré Syndrome (GBS). GBS is a polyneuropathy of autoimmune origin, and its onset 
is closely linked to previous infection by various pathogens (28) including ZIKV. The 
destruction of peripheral nerves causes facial palsy, distal limb paresthesia and muscle 
weakness, rapidly progressing to paralysis (29). In severe cases, paralysis of the respiratory 
muscles can result in breathing difficulties and the need for intensive care (30). 
As of today, there is no cure or approved therapy for neither CZS nor GBS and patients are 
treated with supportive care.  
1.2.3 ZIKV life cycle  
To be able to develop new treatments, a deep knowledge of ZIKV life cycle steps and the 
molecular mechanisms underlying infection is needed. However, as of today, not all steps of 
ZIKV replication have been investigated in detail. Generally, ZIKV replication is thought to 
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be similar to other members of the Flaviviridae family and can be divided in the following 
steps: attachment and entry, translation of the viral RNA into proteins, replication of the virus 
genome, assembly and egress from the cell (31). For most of these steps viruses use and abuse 
various host cell factors and machineries, which determines their ability to infect and propagate 
in different tissues and cells, also called viral tropism.  
ZIKV has been found to have a broad tissue tropism including skin, blood, brain, retina, 
placenta and testis (32–36). Notably, the susceptibility of these cells and tissues to ZIKV 
infections explains the pathology caused by ZIKV infection and its modes of transmission. 
To enter any of these target cells, viruses need receptors which can directly or indirectly 
facilitate its incorporation to the cell. While the exact entry receptor for ZIKV is still unknown, 
several candidates are under discussion. Due to the previously mentioned similarities between 
Flaviviruses, research has focused on two distinct families of transmembrane 
phosphatidylserine receptors: TIM (TIM1, TIM3 and TIM4) and TAM (TYRO3, AXL and 
MER). Both of these receptor families are known to be important for DENV entry (37), and 
they are also known to regulate apoptosis and innate immune functions of host cells (38,39). 
However, contrary to initial reports of AXL being very important for ZIKV entry to the cells 
(40,41), several studies suggest that none of the receptors mentioned above is indispensable for 
the ZIKV entry process (42,43).  
Following attachment to its yet-to-be-determined host cell receptor, ZIKV particles are 
internalized by endocytosis and trafficked to endosomes (44). The acidic environment in the 
endosome facilitates a conformational change of the flavivirus envelope protein prompting 
fusion of the viral and endosome membranes and release of the genome (45).  
 




The ZIKV genome is a single stranded (ss) positive sense (+) RNA with a length of 10,794 kb, 
and it is organized in a single open reading frame. It codes for a polyprotein which is later 
cleaved proteolytically into three structural and seven non-structural proteins, which are 
important for viral replication (46) (Figure 1). The release of the genome is followed by a first 
translation step, which is crucial to produce all viral proteins needed for viral replication 
including the viral RNA-dependent RNA polymerase (RdRP) (NS5).  
The RdRP initiates virus replication by synthesizing a (-)RNA intermediate from the 
complimentary (+)ssRNA. This (-)RNA is subsequently used as a template to generate many 
(+)ssRNA copies (47). Similar to other Flaviviruses, ZIKV replication takes place in so called 
replication factories (RFs) in the endoplasmic reticulum (48). The spatial segregation of viral 
and cellular compartments probably provides protection for the viral RNA from host nucleases 
and from detection by the innate immunity sensors. Through pores in the RFs the resulting 
(+)ssRNA is released into the cytosol (48), where it serves multiple purposes: production of 
new virus proteins, formation of new RFs and packaging into new virus particles.  
The still immature and non-infectious virions are assembled in the ER, consisting of the E and 
prM proteins on a lipid membrane bilayer and the nucleocapsid in the core formed by C protein 
and RNA (49). To be able to undergo membrane fusion in the next cell, the virus particles need 
to mature (50,51). This happens during the transit through the trans-Golgi-network towards the 
cell surface, when the prM protein is cleaved to M by a Furin-like protease. In the final step, 
virus particles are released to the extracellular environment by exocytosis (Figure 2). 
 





The mortality and morbidity caused by emerging diseases is increasingly high (52–55), and 
new and more frequent outbreaks demonstrate how vulnerable the lack of vaccines and 
therapeutics leaves us in the face of viral emergence. While the development of highly 
efficacious and safe vaccines against SARS-CoV-2 within just one year, gives hope for future 
pandemics and redefines the limits of vaccine development (56), it does not make antivirals 
obsolete. New preferably broadly active antivirals are needed to bridge the time until vaccine 
development and deployment, and to provide treatment opportunities for individuals who 
cannot be vaccinated. This is why extensive drug discovery efforts are still needed to ameliorate 
the medical need and economic burden of emerging viruses.  
1.3.1 Host targeting and direct antivirals 
When fighting virus infections, two distinct therapeutic strategies can be implemented: crucial 
parts of the virus can be targeted directly (directly acting antivirals) or cellular proteins and 
machineries indispensable for virus replication can be targeted (host-directed antivirals). Both 
approaches come with advantages and drawbacks (57). 
Directly acting antivirals are very specific. They target one particular viral protein, which 
comes with the disadvantage of needing to find and confirm a good, druggable viral target. In 
addition, it can also limit the utility of the newly identified antivirals to just one virus. 
Furthermore, a hallmark of RNA viruses like ZIKV is their high mutation rate leading to 
production of many genetic variants (quasi species) in every replication round (58). Directly 
targeting an important virus protein constitutes a high selection pressure, and results in the rapid 
selection of resistant virus variants. Combining several directly acting antivirals with distinct 
targets and increasing effectiveness of antivirals can help to reduce development of resistance, 
as has been shown very impressively by treatment regimens for human immunodeficiency 
virus type 1 (59). Also, by targeting the virus itself, less host impact and thus less side-effects 
can be expected. 
Host targeting antivirals, on the other hand, can slow down the development of resistance, since 
it will require more time for the virus to adjust its entire replication machinery. Another 
advantage is the potentially broad antiviral activity. This is especially true for Flaviviruses, in 
which the replication process and use of host machinery is quite conserved. However, this 
comes at the cost of potential side effects, as a result of blocking pathways important for the 
host cell themselves (60,61). Furthermore, identifying the host target can be a long and 
challenging process.  
An antiviral which has been used experimentally against various emerging viruses, including 
Lassa virus (62) and Crimean-Congo hemorrhagic fever virus (63) is ribavirin. Ribavirin is a 
guanosine analogue, with demonstrated broad spectrum activity against DNA and RNA 
viruses. Ribavirin’s mode of action is not completely clear, but most likely it is a combination 
of direct effects from RdRP inhibition, interference with RNA capping, and from insertion of 
lethal mutations as well as indirect antiviral effects through immunomodulatory effects (64). 
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Ribavirin has also been reported to inhibit ZIKV infection in vitro in various cell models and 
in vivo (65,66).  
1.3.2 Screening for new antivirals 
In the past decade completely new approaches to drug screening have been developed and are 
becoming widely accessible. The increasing convenience and affordability of genome wide 
screening methods like RNA-interference, haploid cells, and the CRISPR technology (67,68) 
combined with the accelerated development in the field of computational biology and 
chemistry provides new ways and opportunities for drug screening (69). 
Apart from the very new ways of screening, other approaches can be applied to identify new 
antiviral substances. In line with the two main antiviral strategies - virus- vs host-directed - a 
target-based approach and a phenotypic screening approach can be used, both of which provide 
unique opportunities and challenges.  
Target-based screening approaches usually use a biochemical assay to test drug-candidates 
specifically for their activity against a predefined target. The use of a target-based approach 
provides the opportunity of rapid lead compound optimization, once a promising candidate is 
identified. However, there is no guarantee that an inhibitor identified in a biochemical assay 
will also work in cells. 
Phenotypic screening assays are typically cell- or organism-based, which mean they primarily 
identify compounds which work in a physiological cellular context. This type of screening is 
largely unbiased, allows identification of both cellular and direct inhibitors and can be used to 
uncover new host-pathogen interactions as well as new drug targets with potentially broad-
spectrum activity. However, for phenotypic screening approaches it is crucial which cell or 
organism model is chosen for the screening, because the performance of a compound might 
differ across cell types and species.  
1.4 MODELS IN ZIKV RESEARCH 
Independently of the screening approach, cellular and organism-based models are needed to 
confirm and optimize potential antiviral treatments, as well as study host and virus biology. 
However, model development is challenging. Viral tropism and species-specific interactions 
of viruses with the host lead to poor replication of many viruses in cellular models and 
differences in host reactions between humans and animals used in studies. The following 
chapter summarizes various systems developed to model ZIKV infection, to facilitate research 
on ZIKV and promote the development of antiviral therapies and vaccines.  
1.4.1 Cell culture & organoids 
Two-dimensional (2D) cell culture models are a cheap, established and highly controlled way 
to study many aspects of the virus life cycle as well as the host reaction, and they have been 
used intensively to study ZIKV (70). In a 2D monolayer, infections can spread very efficiently, 
since all cells are accessible to the virus at the same time. These models are very useful to study 
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viral tropism and show if the virus in question can infect the cells used as a model. Since many 
events in the virus life cycle are very similar in cells and organisms, results can often be 
extrapolated, and cell lines are a good starting point for antiviral drug development.  
Vero cells, green monkey kidney cells, are a cellular model commonly used in the virology 
field, because they support the growth of many different viruses, they are used to isolate viruses 
and measure viral titers (71). Nevertheless, while they support the growth of ZIKV (72), they 
are not the most physiologically representative model. Keeping in mind that ZIKV infection 
primarily causes microcephaly in the developing brain, brain derived cell cultures represent a 
more relevant model. U87 cells are a glioblastoma cell line (73) which has been shown to 
sustain ZIKV infection, and also been used for some mechanistic studies, like studying 
inflammasome activation upon ZIKV infection (74).  
Even if they are of a more relevant origin, U87 is a cancer cell line and two dimensional. In 
contrast to this, the human brain is an extraordinarily complex organ, and the interaction of 
various different cell types is crucial for its function. The complexity and cellular diversity of 
the human brain is one reason why there is a lack of accurate models to study the human brain. 
To further complicate matters, the remarkable qualitative and quantitative differences between 
animal and human brains e.g. between human and rodent brains (75), make the development 
of suitable animal models challenging.  
 
Figure 3: Schematic visualization of the complexity and homogeneity of cerebral organoids in relation to 
2D cell cultures and the human brain.  
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To tackle this problem, three-dimensional (3D) cell cultures have recently been developed from 
skin-derived induced pluripotent stem (iPS) cells, to mimic more closely the natural 
physiological conditions (Figure 3), and especially the complex cytoarchitecture. These models 
have been used successfully to study microcephaly caused by ZIKV infection (76,77). 
1.4.2 Blood 
While conventional 2D and modern 3D cell cultures are good models to study virus 
pathogenesis and host interactions, a crucial drawback of cell lines is their genetic and 
phenotypic homogeneity. Moreover, many cell lines are derived from tumors and thus have 
intrinsically altered host pathways (78) and immune responses (79). Primary cells on the other 
hand resemble the original tissue quite well, however, they are not easily accessible and are 
difficult to work with.  
Blood remains the most convenient, cost-effective and easy to work with primary tissue from 
either patients or healthy donors. Since ZIKV has been shown to infect peripheral blood 
mononuclear cells (PBMCs) (80), PBMCs have been used in research to model ZIKV infection 
and study host immune responses.  
1.4.3 Animal models of ZIKV infection 
While many features of virus infection are similar between cell culture, especially primary 
cells, and the organism as a whole, certain complex host defense strategies, such as the adaptive 
immune response, are not found in cell culture. Also, the main pathologies caused by ZIKV 
infection are serious neurological disorders in the fetus infected during pregnancy, another 
complex system which cannot be studied in cell culture. This highlights the need for a more 
sophisticated model to study ZIKV comprehensively.  
Reflecting this necessity, several mammalian models of ZIKV infection have been developed 
since 2016. The most studied model organisms are immunodeficient mice (81), which can 
provide valuable insights into pathogenesis of ZIKV infection. However, the relevance and 
transferability of these data for the human disease are questionable, since their immune 
response upon infection is altered and it has been shown that susceptibility to infection largely 
differs with the age of these mice (82). Nonhuman Primates (NHPs), on the other hand, provide 
a much more relevant model, especially for ZIKV infection during pregnancy (83). Among the 
common features of ZIKV infection in humans and NHPs is vertical transmission from mother 
to fetus, as well as fetal abnormalities similar to CZD regardless of the severity of the maternal 
infection (84,85). However, drawbacks of using NHPs as disease models include ethical 
considerations, high costs and extended experimental time due to the relatively long duration 
of pregnancy.  
A more cost- and time-efficient model to study ZIKV is the chicken embryo. Historically, 
chicken embryos have been a powerful tool to study developmental biology, embryology, as 
well as teratogenicity of drugs (86,87). Furthermore, chicken embryos are a well-established 
and widely used model in virus research and vaccinology (88,89). A few studies have 
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demonstrated the ability of ZIKV to replicate potently in infected chicken embryos (90,91), 
and causing a similar pathology as seen in humans: virus replication in various organs, 
microcephaly and enlarged ventricles (91,92).  
Overall, many complex models have been established and are constantly being developed to 
study ZIKV infection and facilitate drug and vaccine development, each with their own set of 
advantages and limitations.  
1.5 COMPOUND PROFILING  
Despite many new and highly sophisticated disease models, a prevailing challenge in drug 
discovery is to identify the molecular target(s) and pinpoint the specific effect of the drug of 
interest on cellular pathways, especially if it is a previously uncharacterized molecule. Many 
drugs also have poly-pharmacological effects, affecting not only one specific target, but 
manipulating diverse cellular pathways. Recently, new approaches like thermal proteome 
profiling (TPP), have opened new ways of compound characterization. TPP enables the 
monitoring of changes in protein thermal stability introduced through protein-drug interaction 
across the proteome using quantitative mass spectrometry to quantify these changes and thus 
facilitating the identification of drug targets (93). 
1.6 THE DIAGNOSTIC LANDSCAPE FOR VIRUSES AND 
CHALLENGES IN THE DIAGNOSTICS OF EMERGING VIRUSES 
To fight a newly emerging pathogenic virus, timely availability of accurate diagnostic tools is 
indispensable. From a single-patient perspective, knowledge about what causes the patient’s 
disease is needed to guide treatment and facilitate recovery. From a societal and public health 
perspective, implementation of effective disease surveillance and control is impossible without 
widely available, sensitive and specific tests. Generally, there are two approaches to virus 
diagnostics: direct and indirect diagnostics.  
1.6.1 Direct virus detection methods  
Direct diagnostic tools detect virus material, like viral proteins or its nucleic acids in patient 
samples. These approaches can be based on various different technologies explained in the 
following paragraph.  
1.6.1.1 Electron microscopy 
The most immediate virus detection method is detection of the virus directly from a patient 
sample using electron microscopy. However, especially in samples with a low virus load, it 
might be necessary to enrich the virus by isolation in cell culture to increase the sensitivity of 
the method (94).  
1.6.1.2 Virus isolation 
For a long time, virus isolation from patient samples was the gold standard method in 
virological diagnostics. In this approach, the patient sample is cultured on cells, tissue or even 
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in animals until a cytopathic effect (CPE), virus induced cellular destruction, is detected. After 
detection of CPE follow up tests are needed to determine which virus has been isolated. If there 
is a clear suspicion based on the clinical presentation of the patient, the follow-up can be 
targeted using qPCR or antigen tests. If the pathogen is unknown, a non-targeted method like 
electron microscopy or next generation sequencing (NGS) is needed to determine which virus 
has been isolated. The virus strains isolated from patient samples are also a valuable tool in 
research to study pathogenicity and compare virulence between various virus strains (94).  
However, there are several drawbacks to virus isolation. It is highly time consuming, taking 
several days at the least. Furthermore, virus isolation is subject to significant biological 
variation, and depends on the permissiveness of cells or tissue to the virus in question. To add 
another layer of complication, not all viruses cause CPE, making a negative result hard to assess 
without resource-heavy follow up-tests like NGS. Furthermore, especially in the case of 
emerging RNA viruses, virus isolation usually entails access to expensive laboratory 
infrastructure, skilled personnel, and high safety measures to contain the biorisks associated 
with experiments of this kind. Oftentimes these resources are not available in low- and middle-
income countries.  
All these drawbacks question the suitability of virus isolation for primary diagnostics, where 
the aim is a timely and precise answer. Likewise, in the past decade, the emergence of ever 
new and more sensitive molecular virus detection methods started to replace virus isolation in 
routine virus diagnostics. Nonetheless, especially for newly emerging infections with unknown 
pathogens, isolation oftentimes remains the crucial first step to discover a new pathogen and 
be able to characterize it.  
1.6.1.3 Virus antigen detection 
Immunoassays in either liquid or solid form are a frequently used technology to detect virus 
antigens in patient samples or as follow up test after virus isolation. The principle is capturing 
virus antigens from the patient sample with an antibody, which can be either in solution or 
attached to a membrane. In a second step, the complexes formed are identified by a detection 
reaction.  
In the last two decades, technologies to detect nucleic acids have become more accessible and 
affordable, and especially qPCR has become the gold standard in detecting virus diagnostics 
(94). qPCR is a highly specific diagnostic tool, has a fast turn-around time of only a few hours 
from sample arrival to result and offers opportunities to react quickly to virus changes, like the 
emergence of new strains (94). In recent years the portfolio of nucleic acid detection methods 
in virus diagnostics has been complemented by isothermal amplification techniques like loop-
mediated isothermal amplification (LAMP) (95) or rolling-circle amplification (RCA) using 
padlock probes (PLPs) (96). PLPs are linear, single stranded DNA oligonucleotides which 
consist of complementary target arms (15-20 nucleotides in length) and a longer, non-
hybridizing backbone (40-50 nucleotides in length). Binding of the target arms to their 
respective target results in a circle which is linked through DNA ligation. After circulization, 
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the probes are amplified using a DNA polymerase. Digesting the amplification product and 
repeating the ligation and amplification step are called Circle-to-Circle amplification (C2CA) 
and increases sensitivity. Detection of the rolling circle products is performed using fluorescent 
labelling. Advantages of the method include isothermal amplification and high specificity, 
because perfect alignment of hybridization arms and ligation site are required (97,98).  
Another trend seen in the past ten years was an increasing number of multiplex tests which 
facilitate the detection of pathogens usually grouped by the clinical presentation, like pathogens 
causing respiratory infections or meningitis. Most of these devices are based on detection of 
nucleic acid detection (99). While this approach is mostly limited to identifying previously 
known pathogens, it helps to streamline and speed up diagnostics. Several of these multiplex 
tests are increasingly easy to handle and could even potentially be used by trained staff as point-
of-care diagnostics (100). 
Furthermore, the increasing affordability of sequencing technologies opens up even more 
possibilities to use these technologies. In the ongoing COVID-19 outbreak setting, these tools 
have proven to be invaluable to determine how the virus evolves into new lineages and coupling 
this information to new phenotypic features like increased transmissibility (101).  
However, an essential disadvantage of any method using nucleic acid detection, is that it cannot 
predict infectivity. In this context, the high sensitivity of the method is a drawback. It has been 
shown that viral RNA can be detected in various patient samples long time after infection, and 
the significance for patient outcome and infectivity are often unclear (102,103). Methods like 
virus isolation can provide insights on infectivity. 
1.6.2 Indirect detection methods  
Indirect diagnostics are based on the immune reaction triggered by virus infection. Typical 
assays used to determine the existence of antibodies towards a virus in patient serum are 
enzyme-linked immunosorbent assay (ELISA) or immunoblots (94). As a common principle 
synthetically produced virus antigens are used to capture potential antibodies present in the 
patient sample and the complexes formed between the virus proteins and patient antibodies are 
detected by a detection reaction (94). With the increasing recognition of the role of cellular 
immunity induced by T helper and cytotoxic T cells towards viruses, assays are being 
developed to measure cellular immune responses. In enzyme-linked immunosorbent spot 
(ELIspot) assays, patient cells are stimulated by virus antigens. The cytokines released by the 
cells as a result of the stimulation are captured on a membrane coated with antibodies for 
cytokines, and the complexes are then visualized by a detection reaction. Currently ELIspot 
assays are not part of routine diagnostics for viral diseases but are used to assess vaccine 
efficacy and for research purposes (104–106).  
ELISAs, immunoblots and ELIspot assays are highly dependent on the peptides and proteins 
used as antigens to stimulate cells or capture antibodies. Especially in the beginning of a 
pandemic, when there is little knowledge about a virus, the production of highly specific 
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antigens might be difficult to achieve, leading to sensitivity issues in the detection. In this 
context also the variability in the human immune response pose additional challenges (107). 
Immunofluorescence (IF) assays on the other hand are very resource heavy, since an IF 
microscope is needed for the assay. If there are no commercial IF assays available, similar 
resources are necessary as described above for virus culture, once again disadvantaging low-
income settings.  
Furthermore, cross-reactivity of antibodies between different viruses of the same family is a 
known issue in all indirect assays and has been shown for example for members of the Flavi- 
and Coronavirus families (108–110). Cross-reactivity affects test specificity and can make a 
specific diagnosis difficult, especially in geographical regions where many different viruses 
from the same family are circulating.  
All in all, the virus diagnostics field has seen a technological revolution in the past three 
decades and moved from cell-based virus isolation as gold standard to broad application of 
highly specific molecular diagnostic methods. However, continuous research and development 
is needed to improve the methods available today and provide new innovative ways for virus 








2 DOCTORAL THESIS 
2.1 RESEARCH AIMS 
The aim of this thesis was to show how various cellular and organoid models can be used to 
identify and characterize new antivirals and develop new diagnostic tools.  
Specific contribution of each paper to the aims 
• Paper I - Novel broad-spectrum antiviral inhibitors targeting host factors 
essential for replication of pathogenic RNA viruses 
- Use of an image-based phenotypic antiviral screening assay to identify host-
targeting antivirals 
- Application of the image-based phenotypic antiviral assay to determine the 
antiviral activity of the newly identified antivirals against Coronavirus 229E (CoV 
229E) and SARS-CoV-2  
 
• Paper II - Broadly active antiviral compounds disturb Zika virus progeny release 
rescuing virus-induced toxicity in brain organoids 
- Transfer of the image-based phenotypic antiviral screening assay to a different cell-
virus-system 
- Application of the image-based phenotypic antiviral assay in ZIKV infected 
glioblastoma cell line U87 to determine the therapeutic window of newly identified 
antivirals 
- Use of an iPS cells derived 3D organoid model to study the antiviral effect of 
identified antiviral compounds 
 
• Paper III - Circle-to-circle amplification coupled with microfluidic affinity 
chromatography enrichment for in vitro molecular diagnostics of Zika fever and 
analysis of anti-flaviviral drug efficacy 
- Use of ZIKV infected glioblastoma cell line U87 to establish circle-to-circle 
amplification coupled with microfluidic affinity chromatography enrichment 
(C2CA-μACE) as a new diagnostic tool  
- Use of PBMCs to benchmark C2CA-μACE relative to RT-qPCR and study 








2.2 RESULTS  
Recent outbreaks of pathogenic RNA viruses like SARS-CoV-2, EBOV or ZIKV highlight the 
need for new antiviral strategies as well as diagnostic tools to be better prepared for emergence 
of ever new pathogens. The papers included in this thesis feature the use of various cellular and 
organoid models to facilitate the development of host-targeting antivirals and new diagnostic 
tools against emerging viruses. 
2.2.1 Paper I - Novel Broad-Spectrum Antiviral Inhibitors Targeting Host 
Factors Essential for Replication of Pathogenic RNA Viruses 
In this study, an image-based phenotypic antiviral screening assay was established using 
Hazara virus (HAZV) infected SW13 cells. HAZV is an RNA virus, which is not pathogenic 
for humans and can be used at biosafety level two laboratories but serves as a model for 
Crimean-Congo hemorrhagic fever virus. The main readouts of this assay were cell survival 
measured by nuclei count, number of infected cells as share of DMSO treated controls and 
virus progeny release, determined by titration of collected supernatants on fresh cells. Using 
the screening assay, 425 compounds from an in-house library of host targeting small molecular 
inhibitors were tested for their antiviral activity, revealing two close analogues TH3289 and 
TH6744 as hit compounds. The antiviral activity of both compounds against HAZV was 
confirmed by determining the antiviral effect in a dose-dependent way and showing a 
therapeutic window between the antiviral effect on the viral titer and cell viability. Moreover, 
both new antiviral compounds were confirmed to have a broad-range antiviral activity against 
several pathogenic RNA viruses including SARS-CoV-2, EBOV and Crimean-Congo 
hemorrhagic fever virus.  
Originally both TH3289 and TH6744 were designed to inhibit human 8-oxoguanine 
glycosylase 1 (OGG1). However, the antiviral activity of the compounds was shown not to 
depend on their ability to inhibit OGG1. As a next step, to investigate the target of the new 
antiviral compounds in more detail, thermal protein profiling was performed with TH6744. 
Using this approach, the compound was shown to affect proteostasis pathways and disturb 
interactions between cellular HSP70 complex and viral proteins.  
2.2.2 Paper II - Broadly Active Antiviral Compounds Disturb Zika Virus 
Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids 
In the second study, the previously established image-based phenotypic antiviral screening 
assay was transferred to test the antiviral activity of in-house antiviral compounds in Zika virus 
infected cells. A comparison between the antiviral screening from Paper I revealed the same 
compounds to be active against both HAZV and ZIKV, confirming the broad antiviral activity 
of the compounds. Next, the therapeutic window of the top-hit compounds was demonstrated 
in several cellular models of ZIKV infection by comparing the dose-response analysis of the 
antiviral effect and cellular toxicity.  
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To study the antiviral activity of the compounds in a more physiological model of ZIKV 
infection, a 3D organoid model was established using human iPS cells. The novel antiviral 
compounds showed an antiviral effect on both infected organoids and viral progeny production 
and additionally reversed ZIKV induced neurotoxicity.  
Subsequently, the compound’s mechanism-of-action was studied by investigating intra- and 
extracellular ZIKV RNA levels over time and doing various time-of-addition experiments. 
Interestingly, ZIKV RNA levels were not impacted by treatment with TH6744. Instead, a rapid 
reduction of progeny release was detected even upon short treatment of 2h at late stages of 
infection. To investigate this finding further, the budding efficiency was studied but revealed 
no difference in the reduction of infectious virus particles between intra- and extracellular 
ZIKV particles. Altogether, the mechanism of action studies narrowed the mechanism-of-
action down to impairment of formation of new virus particles in the late ZIKV lifecycle steps. 
It also revealed that TH6744 does not only rescue ZIKV induced pathologic phenotypes in cells 
and organoids, but also reduces virus transmission.  
In summary, Paper I and Paper II highlight the value of various cellular and organoid models 
in the development and characterization of new host-targeting broad-spectrum antivirals. 
2.2.3 Paper III- Circle-to-circle amplification coupled with microfluidic affinity 
chromatography enrichment for in vitro molecular diagnostics of Zika 
fever and analysis of anti-flaviviral drug efficacy 
In Paper III, the development of a new diagnostic tool for ZIKV nucleic acids is described. 
Sequences from ZIKV genetic material were detected from ZIKV cDNA using padlock probes, 
targeting various region of the ZIKV genome, in particular regions coding for capsid (C), 
precursor membrane (PrM), envelope (E) and non-structural proteins (NS). Detection was 
followed by two rounds of Circle-to-Circle Amplification (C2CA) combined with a 
microfluidic affinity chromatography enrichment (μACE) platform. 
In a first step the limit of ZIKV RNA detection (LoD) was determined for both a single round 
of rolling circle amplification (RCA) and two rounds (C2CA) of RCA using a dilution series 
of a single ZIKV synthetic ssDNA. A comparison of RCA and C2CA performance revealed 
C2CA to be superior and decrease the LoD by 3-fold, to be between 103 to 104 copies/mL. 
Consequently, C2CA was chosen for further method development and validation.   
Next, ZIKV RNA extracted from cell culture supernatant from in vitro infected U87 was used 
to find an optimal method to determine the fluorescence of the C2CA products. Altogether 12 
padlock probes were used to amplify the ZIKV RNA from the supernatants of infected U87 
cells, and thereafter fluorescence was measured using either glass slides or μACE. Both 
measurements led to an effective detection of ZIKV compared to the negative controls. 
However, μACE provided a better signal to noise ratio through a higher selectivity of the μACE 
towards RCPs compared to artefacts like non-specific fluorescent clusters or debris. Thus, 
μACE chosen as the detection method of choice for the following experiments.  
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Subsequently, to benchmark C2CA-μACE against a gold standard diagnostic method, viral 
RNA obtained from in vitro infected PBMCs was quantified by both RT-qPCR and C2CA-
μACE, revealing a good correlation between both methods as depicted by a Pearson correlation 
coefficient (r) above 0.8. Subsequently, the method was validated in in vitro infected PBMCs 
from three healthy donors infected with ZIKV and treated with Ribavirin, an FDA approved 
antiviral drug. The subsequent reduction in ZIKV RNA by 1-log detected by RT-qPCR was 
mirrored by the C2CA-μACE method.  
In summary, this study shows a promising approach to develop a highly sensitive, simple and 
cost-effective point-of-care viral diagnostics tool. Moreover, it is demonstrated how using cell 






The WHO has long been advocating for increased research and development efforts, to create 
new antivirals and diagnostic tools for diseases with epidemic potential (111).  
A major obstacle to the development of new antivirals is the lack of good models to study viral 
diseases. Developing new approaches, refining and improving models used in virus research is 
critical to advance drug discovery. This thesis studied the use of various cell models in antiviral 
drug discovery and diagnostics development, highlighting advantages and disadvantages of the 
various models.  
2.3.1 Using phenotypic screening as an approach to antiviral drug-discovery 
In Paper I we present an image-based phenotypic screening assay using the adrenal gland 
small cell carcinoma cell line SW13 and HAZV. In contrast to many other screening assays 
published, infectious virus is used in the assay presented, and thus our system allows to study 
the effect of the tested compounds on all virus lifecycle steps. There is a plethora of approaches 
to antiviral screening, ranging from screening systems using virally induced cytopathic effects 
as a readout (112,113) to screening using replicon systems (114,115). Very often these replicon 
systems are unable to produce infectious viable virus progeny (116), making them especially 
interesting in the context of emerging RNA viruses, many of which entail handling at facilities 
with high biosafety. A drawback of using replicon systems for antiviral screening is that 
without production of infectious virus progeny, not all steps of the virus life cycle can be 
examined, making the antiviral screenings blind towards drugs that impair virus progeny 
release.   
The assay design utilized in Paper I allows to check for inhibition of all virus life cycle steps, 
while in addition mimicking the real-life situation of treatment following infection. While there 
are previous reports of image-based screening for antivirals using infectious virus in cell lines 
(117,118), in most published studies, the cells were pre-treated with the drugs before virus 
infection and only primary virus infection was studied not virus progeny release (117,118). 
This approach biases the assays towards drugs that inhibit the virus in early steps of the virus 
life cycle, like viral entry or translation and RNA synthesis.  
In Paper II the adaptability of the image based phenotypic screening approach is highlighted 
by a transfer of the assay from HAZV infected SW13 cells to ZIKV infected U87 cells. A 
versatile assay is important in the development of drugs against emerging viruses, to be able to 
adapt quickly, and transfer the assay to a new virus-cell-system for drug development or testing 
against previously unknown viruses. 
Despite the advantages mentioned above, the image-based phenotypic screening approach used 
in Paper I and Paper II has some limitations. One inherent limitation comes with the usage of 
antibodies to detect the different viruses. Firstly, this detection method is highly dependent on 
the availability of specific antibodies with low background. Especially for newly emerging 
viruses the development of good tools to use in an image-based assay can take a while and limit 
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immediate application of the assay. Furthermore, different viral proteins are expressed at 
different timepoints of infection in different quantities (119). Thus, during assay development, 
the assay needs to be well controlled, for example by using antibodies against several viral 
proteins and comparing them, as well as performing an infection-time and -dose kinetic study 
to determine optimal experimental conditions. To exclude antibody-based bias, 
immunofluorescence staining of ZIKV NS1 and Capsid proteins was compared in Paper II 
and both antibodies were demonstrated to have the same sensitivity for detecting ZIKV-
infected cells. 
By choosing imaging as a readout, the phenotypic screening assay presented in Paper I and II 
provides a single-cell resolution, enabling studying the effects of virus infection and treatment 
on each cell. But, in the studies presented, only nuclei count determined by DAPI staining is 
used as a readout for cellular toxicity. While DAPI staining is comparably easy to determine 
and analyze, a more thorough assessment of the host cells could provide insights into the 
mechanism of action of compounds on the host cells. Morphological profiling of cells by new 
techniques like Cell Painting, can maximize the available information extracted from image 
based screenings and foster antiviral drug discovery (120,121).  
2.3.2 Organoids as models to study Zika virus infection 
In Paper II an iPS cell derived 3D brain organoid model is established and used to validate the 
top hits compound identified in the image-based phenotypic screening assay. 3D models have 
been shown to be advantageous over 2D cell culture models in mimicking some of the brain’s 
architecture and complexity (75). In the context of neurotropic infections, 3D brain organoids 
are valuable tools to investigate virus spread and infection dynamics over time, viral tropism, 
virulence, and even long-term effects of virus infection.  
In 3D models, infection is much less efficient than in 2D models, since only certain surface 
parts of the organoid are accessible for infection. To take this into consideration, in Paper II 
infection time was extended to 24h to establish ZIKV infection in the organoid models. 
Moreover, there was an increase in progeny production with increasing dose and time of 
infection, reflecting infection spread through the organoids as more cells got infected over time.  
3D brain organoids significantly contributed to connecting ZIKV neurotropism to fetal 
microcephaly after maternal ZIKV infection during pregnancy (122). In the study presented 
here, ZIKV neurotoxicity was shown through organoid viability reduction as well as reduced 
production of ZIKV progeny by organoids at the highest infection dose at 7 dpi. The 
neurotoxicity enabled highlighting the phenotypic rescue upon treatment with our compounds, 
illustrated by an increased viability, reduction of primary infection and ZIKV progeny 
production. However, further characterization of ZIKV neurotoxicity and its rescue seen in our 
model would be highly interesting. Cugola et al. and Qian et al. were among the first to describe 
that ZIKV causes apoptosis in neuronal progenitor cells, limiting their viability and impairing 
organoid growth (123,124). It would be of interest to see the effects of our treatments on 
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apoptosis and cell proliferation, and especially if certain cell-types are particularly affected by 
ZIKV infection and treatment.   
A problem faced in Paper II was the previously described variability between organoids (125): 
while in some organoids ZIKV infection led to a strong reduction in viability and size, other 
organoids infected in the same culture dish remained seemingly unaffected. This unique effect 
of ZIKV on each organoid entailed a high intra- and inter-experimental variability. 
Furthermore, it made it especially difficult to study changes in organoid size, without following 
up on each organoid separately. On the other hand, this variability also reflects the real-life 
setting, since only less between 2.5-5% of babies born to mothers with ZIKV infection during 
their pregnancy develop birth defects (26,27). In the rest of the cases, the fetuses do not suffer 
from microcephaly, despite a maternal ZIKV infection during pregnancy.  
Even if 3D brain organoids come closer to mimicking the human brain than 2D cell cultures, 
some important features are still missing. Missing parts include key determinants of infection 
in an organism like the blood flow and especially an immune reaction. This drawback of the 
model became apparent in the studies of ZIKV infection in human brain organoids presented 
here, as it was not possible to detect cytokine secretion in ZIKV infected organoids at 1 and 7 
dpi (data not shown). However, there are various promising approaches to improve brain 
organoid models to include these and other features and make the method even more appealing 
and comprehensive. Recently there were reports of organoids containing microglia and 
responding to ZIKV infection by increased expression of pro-inflammatory genes (126) and of 
organoids containing a vasculature like system (127). Furthermore, organoids containing cells 
from the choroid plexus and producing cerebrospinal fluid were developed, enabling future 
investigations of drug-neurotoxicity and the blood brain barrier (128).  
Altogether, 3D brain organoids already are a valuable tool in antiviral drug development, but 
it remains interesting to see if the developments in the field will be fast and comprehensive 
enough for organoids to become a true alternative to for example animal studies.  
2.3.3 Using cellular models to develop diagnostics 
While in Paper I and II, cell-based models were used in antiviral drug discovery, in Paper III 
the focus was on facilitating diagnostics development.  
In our study, using an established cell line for preliminary studies to optimize the C2CA-μACE 
system offered a reliable, readily available and easily reproducible source of samples. A similar 
approach has been previously used by other researchers in the establishment and pre-testing of 
new diagnostic methods (129).   
After optimal conditions were determined, in vitro infected PBMCs were used to characterize 
the method more in detail. An advantage of this approach is that it mimics wide parts the real-
life scenario of human infection. ZIKV replication in human PBMCs before collection of 
supernatants for RNA extraction and detection by qPCR and C2CA-μACE system is 
comparable with what happens in patients with exception of the mosquito bite. The similarity 
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of the systems is underscored by previously published reports of viremia levels in patients of 
around 104 copies/mL (130,131). Thus viremia levels in patients correspond well to the ZIKV 
levels detect in supernatants from infected PBMCs in Paper III. Alternative approaches used 
human material from healthy donors like plasma or urine spiked with ZIKV RNA (132). While 
the amount of RNA spiked into the sample can be very well controlled, it is also a very artificial 
approach compared to the approach chosen in Paper III.  
To summarize, while cell culture and in vitro infected PBMCs will never replace true patient 
samples for the validation of diagnostic tests, they can be a way to make diagnostics 
development faster and more cost-effective. Furthermore, using in vitro infected blood cells 
can help research groups without access to patient samples to participate in diagnostics 
development. Still, before use in the clinics, the approach would need to be validated 
thoroughly using patient samples with different amounts of virus to determine sensitivity, 
specificity and limit of detection of the C2CA-μACE system. 
 




2.4 CONCLUSIONS AND FUTURE PERSPECTIVE 
Several pandemics occurred in the past decade including the biggest Ebola outbreak recorded 
so far in Western Africa from 2014-2016, the ZIKV epidemic in South America between 2015 
and 2016, and the currently still ongoing global pandemic of COVID-19. Surprisingly, despite 
many warnings and predictions, each of these pandemics caught us off guard, revealing that 
increased efforts are needed in pandemic preparedness, including drug and diagnostics 
development, to be able to react to future threats faster and more efficiently.  
In the phenotypic screening assay used in Paper I and II many terabytes of data were 
generated. To facilitate analysis, data management programs like KNIME were used. However, 
this was only a small step towards automated data analysis and many more tools like artificial 
intelligence (AI), machine learning or deep learning are available and are constantly being 
developed. As science generates more data than ever before, AI and deep learning will play an 
increasing role in drug discovery and development. Not only will it enhance data management 
and analysis of high content assays including imaging assays, but AI can provide completely 
new approaches and impulses to drug discovery. In silico screens were among the first in the 
current COVID-19 pandemic to screen billions of compounds and predict compounds with 
potential antiviral activity against SARS-CoV-2 (133,134). While in silico screens cannot 
substitute for biological assays, they can help to pre-screen a huge number of compounds and 
narrow down potential antiviral drug candidates, or to identify potential drug targets. With 
enough computational capacity, several billions of compounds can be screened in silico, a 
scope which can never be met in biological assays and opens previously unimagined 
opportunities for drug screenings. Blended approaches using machine learning and deep 
learning in several steps of the drug discovery process from target identification, study of 
structure-activity-relationships or analysis of assay results will enhance and speed up the drug 
discovery process and make it more cost-effective, hopefully resulting in new, broadly active 
antivirals in the future.  
Paper II highlights the use of human brain organoids in drug development as a secondary 
model to follow up on top hits from a compound screening. However, the limitations of the 
model like the lack of an immune response prohibited the use of the model for further in-depth 
studies of the compounds and their effect on ZIKV infection in brain organoids. Thus, to 
increase the value of organoids in drug discovery, some key developments will be needed. This 
includes even more neuronal cellular complexity, as well as successful implementation of 
immune cells to be able to assess the immune response. Furthermore, introduction of 
endothelial cells and implementation of microfluidics in the models can simulate a blood flow 
in the organoids, promoting long-term survival of organoids and enabling to simulate the 
distribution of substances and pathogens within the organoids. While collaboration is important 
in research in general, for highly specialized models like organoids, collaboration is key to push 
new developments forward and improve techniques. Sharing protocols and resources as well 
as creating platforms and biobanks can promote the developments described in this paragraph, 
lead to a wide availability of organoids and increase their use in drug discovery.  
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To enable diagnostics early in an outbreak, new and innovative approaches towards virus 
diagnostics are needed. Paper III highlights the development of a sensitive and versatile assay 
to detect ZIKV RNA using RCA. Additionally, the assay has the potential to be scaled down 
towards point-of-care-testing. Taking into account that many viruses with pandemic potential 
(re)-emerge in resource-poor regions with limited access to high-end testing facilities and 
machinery, the development and use of affordable and easy-to-use point-of-care-testing is 
essential. More point-of-care-testing will not only expand access to diagnostics, but also offer 
more opportunities to detect and contain outbreaks on a regional level through increased 
surveillance of the pathogen landscape.  
 
Figure 6: Implications of development for pandemic preparedness 
A key experience during my Ph.D. was, that research is becoming increasingly 
multidisciplinary and collaborative. All projects presented in this thesis were carried out in 
teams of scientists with different backgrounds both within the Helleday Lab but also as 
collaborations with other labs. Increasingly, experts from many different fields are working 
together and sharing expertise. Especially fields like drug discovery or diagnostics 
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development, which are on the cutting edge of many different sciences, like chemistry, biology, 
pharmacology, biotechnology, veterinary and human medicine, will benefit but also depend on 
increasing interdisciplinarity and collaboration and strengthening networks. A success story 
highlighting the importance of collaboration as well as previously built infrastructure and 
capacity in the diagnostics field, is the development of a diagnostic protocol to detect SARS-
CoV-2. The first known case of SARS-CoV-2 infection was traced back to 17th November 
2019, a first viral genome sequence was publicly available on 7th January 2020, and a first 
diagnostic test was provided to the WHO on 13 January 2020 by a group of researchers (135). 
This success was enabled by collaborations between European and Chinese researchers, 
established in response to previous outbreaks, as well as the European Virus Archive. Through 
joint efforts, enough clinical samples and reference RNA sequences could be tested to evaluate 
the qPCR test for specificity and sensitivity and deploy it in record time. To tackle the problems 
of the future, more collaboration will be needed than ever, and strengthening communication 
and networks of scientists from different fields should be a priority. 
Altogether, emergence of unknown viruses and re-emergence of known viruses like Ebola will 
be a challenge for decades to come. With each outbreak there is a gain of knowledge and skills, 
improving the ability to cope with the next outbreak. Still, pandemic preparedness needs to be 
actively developed, including innovative platforms to contribute to fast vaccine development 
and distribution, new broad-spectrum antivirals and diagnostic tools. This work shows how cell 
culture tools of varying complexity can be used in the search for novel drugs and diagnostic 
methods. While none of the models is perfect, each of them comes with their own merits and 
challenges, with unique application possibilities. It will be key to understand better how to 
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